ProQR Therapeutics N.V. announced that the company received Fast Track designation from the Food and Drug Administration for QR-421a for Usher syndrome type 2.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00GlobeNewswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngGlobeNewswire2019-01-02 07:00:242019-01-02 13:11:35ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
